Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Podcasts|March 16, 2025
Diabetes Dialogue: Impact of NovoCare Pharmacy, LillyDirect Self Pay on GLP-1 RA Access
Fact checked by: Patrick Campbell
In this episode, hosts discuss the impact of recently launched direct, cash pay options for people using semaglutide and tirzepatide.
Advertisement
Advertisement
Related to this article
EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.
Advertisement
Advertisement